Videos

Theis outlined her “rule of 3” for evaluating urgent neuro-ophthalmic cases and discussed how retinal findings can reveal early neurodegenerative changes.

Thomas Albini, MD, shares his insights about common cases and the triaging process for patients with ocular trauma.

Mark Bullimore, MCOptom, PhD, FAAO, gave a presentation on myopia management alongside Vishakha Thakrar, OD, FAAO, FSLS, at the conference.

Rahul Tonk, MD, MBA, outlines a session he gave alongside Joseph Allen, OD, FAAO, Dipl ABO, at EyeCon 2025.

Allen discussed therapies such as perfluorohexyloctane and amniotic membrane use, stressing the importance of timely treatment and coordinated patient management.

Panelists discuss how they monitor healed patients with supportive ocular surface treatments, close follow-up schedules, and patient education about recognizing early recurrence symptoms.

Panelists discuss how they treat patients with neurotrophic keratitis (NK) with comorbidities by coordinating with glaucoma specialists, minimizing preservatives, and temporarily discontinuing contact lens wear during treatment.

Diana Canto-Sims, OD, did the digging on private label eyewear companies so you don't have to.

Panelists discuss how cenegermin-bkbj has become their first-line therapy due to its effectiveness, accessibility, and durability, fundamentally changing their approach to dry eye treatment.

Panelists discuss how their treatment approach progresses from amniotic membranes for mild cases to cenegermin-bkbj for more advanced stages, with serum tears used for maintenance therapy.

Panelists discuss how they use staging systems, such as the Mackie classification (mild, moderate, severe), and incorporate corneal sensitivity testing into comprehensive eye exams for better risk stratification.

Panelists discuss how early recognition of stage 1 neurotrophic keratitis (NK) leads to better treatment outcomes and how to identify key risk factors, including diabetes, herpes infections, and long-term glaucoma medication use.

Dan Ignaszewski, executive director of the Alliance for Eye and Vision Research and the National Alliance for Eye and Vision Research, provides insight into the new campaign and how to get involved.

Panelists discuss how to perform corneal sensitivity testing using methods ranging from cotton swabs to the more quantitative Brill esthesiometer, emphasizing that testing should become routine practice.

Panelists discuss how to differentiate neurotrophic keratitis (NK) from dry eye disease and blepharitis by focusing on patient history, chief complaints, and the critical importance of corneal sensitivity testing.

Naureen Haroon, OD, MPH, FAAO, founder of the newly formed WHSIG, said the group's primary aim is to educate the optometric community about why certain eye conditions disproportionately affect women.

Jade Coats, OD, FAAO, gives her insight on what makes EyeCon valuable for eye care providers.

Dr Allen, OD, FAAO, Dipl ABO, plans to talk all things ocular surface for optometrists and ophthalmologists alike.

With FDA approval of LENZ Therapeutics’ Vizz (LNZ100), optometrists now have a daily, non-invasive treatment option for presbyopia, giving patients more freedom and clinicians greater flexibility in care.

Ahmad M. Fahmy, OD, FAAO, discusses how cryopreserved amniotic membrane therapy can successfully address ocular surface complications in complex patients with autoimmune conditions and glaucoma, emphasizing the importance of treating surface disease before surgical procedures to optimize patient outcomes.

Ahmad M. Fahmy, OD, FAAO, discusses how cryopreserved amniotic membrane therapy can effectively treat complex cases of refractory ocular surface disease by addressing multiple contributing factors simultaneously, as demonstrated in a patient aged 81 years with diabetes, eczema, and severe blepharitis who showed significant epithelial improvement after comprehensive treatment.

Ahmad M. Fahmy, OD, FAAO, discusses how cryopreserved amniotic membranes preserve the critical heavy chain hyaluronic acid and pentaxin-3 molecules that deliver anti-inflammatory and antiscarring properties, making them significantly more effective than dehydrated versions for regenerating the ocular surface.

Ahmad M. Fahmy, OD, FAAO, discusses how amniotic membranes can be effectively incorporated into optometric practice as a “reset button” treatment for the full continuum of ocular surface disease severity, from mild to severe cases. This offers patients an alternative to multiple eye drops while being efficiently applied during regular clinic visits.

ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.

Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.

Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.

Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.

Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.

Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.